低耐药病原体风险的社区起病肺炎患者死亡率:β-内酰胺联合大环内酯的影响
该研究基于前瞻性多中心社区起病肺炎队列进行事后分析,纳入594例低耐药病原体风险患者(369例β-内酰胺单药治疗,225例β-内酰胺联合大环内酯治疗)。结果显示联合治疗组30天死亡率显著低于单药组(1.8% vs 13.8%,P<0.001),多变量分析调整后OR为0.28(95%CI 0.09-0.87)。研究还识别了多个独立死亡风险因素。
要点
- 低DRP风险社区起病肺炎中,BLM较BL显著降低30天死亡率。
- 独立死亡风险因素包括PaCO2>50 mmHg、WBC<4000/mm3、不能行走等。
- 评估抗生素效果时需考虑这些风险因素作为潜在混杂因素。
核心结论
- 在低耐药病原体风险的社区起病肺炎患者中,与非抗假单胞菌β-内酰胺单药治疗相比,联合大环内酯治疗可降低30天死亡率。
研究设计与样本
- 基于前瞻性多中心社区起病肺炎队列的事后分析,共纳入594例低耐药病原体风险患者,其中369例接受β-内酰胺单药治疗,225例接受β-内酰胺联合大环内酯治疗。
主要发现
- β-内酰胺单药组30天死亡率为13.8%,联合大环内酯组为1.8%,差异有统计学意义(P<0.001)。
- 多变量分析显示,联合大环内酯治疗与30天死亡率降低独立相关(调整OR=0.28,95%CI 0.09-0.87)。
- 30天死亡的独立预后因素包括PaCO2>50 mmHg、白细胞计数<4000/mm3、不能行走、白蛋白<3.0 g/dL、红细胞压积<30%、年龄≥80岁、呼吸频率>25/min和体温<36°C。
临床怎么用
- 对于低耐药病原体风险的社区起病肺炎患者,可考虑β-内酰胺联合大环内酯治疗以降低死亡率。
- 评估抗生素疗效的随机临床试验时,应关注上述独立死亡风险因素作为潜在混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Drug-resistant pathogen (DRP) risk stratification is important for choosing a treatment strategy for community-onset pneumonia. Evidence for benefits of non-antipseudomonal β-lactam plus macrolide combination therapy (BLM) on mortality is limited in patients at low DRP risk. Risk factors for mortality remain to be clarified. METHODS: Post hoc analysis using a prospective multicentre study cohort of community-onset pneumonia was performed to assess 30-day differences in mortality between non-antipseudomonal β-lactam monotherapy (BL) and BLM groups. Logistic regression analysis was performed to assess the therapeutic effect and risk factors for mortality in patients at low DRP risk. RESULTS: In total, 594 patients with community-onset pneumonia at low DRP risk (369 BL and 225 BLM) were analysed. The 30-day mortality in BL and BLM was 13.8% and 1.8%, respectively (P < 0.001). Multivariate analysis showed that BLM reduced the 30-day mortality (adjusted odds ratio: 0.28, 95% CI: 0.09-0.87) compared with BL. Independent prognostic factors for 30-day mortality included arterial partial pressure of carbon dioxide (PaCO2 ) > 50 mm Hg, white blood cell count < 4000/mm3 , non-ambulatory status, albumin < 3.0 g/dL, haematocrit < 30%, age ≥ 80 years, respiratory rate > 25/min and body temperature < 36°C. CONCLUSION: In patients with community-onset pneumonia at low DRP risk, BLM treatment reduced 30-day mortality compared with BL. Independent risk factors for mortality are potential confounding factors when assessing antibiotic effects in randomized clinical trials.
引用
- Okumura J, Shindo Y, Takahashi K, et al. Mortality in patients with community-onset pneumonia at low risk of drug-resistant pathogens: Impact of β-lactam plus macrolide combination therapy. Respirology. 2017. PMID: 29239493. doi:10.1111/resp.13232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。